Skip to main content
. 2022 Mar 14;10(3):e004129. doi: 10.1136/jitc-2021-004129

Figure 5.

Figure 5

LTX-315-reduced ATP11B is a potential regulator of cancer immunity and PD-L1 expression. (A–B) Overall survival analysis in CD8 +T cell enriched (A) and CD8 +T cell decreased (B) patients with pancreatic cancer with low or high ATP11B expression. (C–E) Positive correlation of ATP11B with PD-L1 in pancreatic cancer. Representative images (C−D) and statistical results (E) of ATP11B and PD-L1 IHC staining in pancreatic cancer tissue microarray. (F–G) Correlation between the expression of ATP11B and abundance of immunoinhibitors (F) as well as tumor-infiltrating lymphocytes (G) across multiple human cancers, as analyzed on the The Cancer Genome Atlas database. (H–M) Maintenance of PD-L1 expression by ATP11B in multiple pancreatic cancer cell lines. Western blotting of PD-L1 expression in ATP11B KD/KO pancreatic cancer cell lines (H−I) and cell lines overexpressing ATP11B (J−K). Flow cytometry showing PD-L1 expression in ATP11B KD/KO pancreatic cancer cell lines and cell lines overexpressing ATP11B (L−M). IHC, immunohistochemical; KD, knockdown; KO, knockout; PD-L1, programmed cell death ligand 1; WT, wild type.